Physician profile
Leland C Smith
NPI 1508084807
$12,742.16
in general payments reported to CMS, 2019-2025
36 companies · $2,169 in 2025
The $2,169 reported for 2025 was more than what 78% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,381 · 2020: $1,206 · 2021: $1,667 · 2022: $1,891 · 2023: $1,635 · 2024: $2,793 · 2025: $2,169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,312 · Education: $285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,312.25 |
| Education | $284.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,792.14 | 2019-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $1,679.70 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,465.77 | 2019-2025 | Blu-U, Odomzo, Ilumya |
| Regeneron Healthcare Solutions, INC. | $976.74 | 2019-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $873.14 | 2019-2025 | Tremfya, Stelara, Simponi |
| Lilly USA, LLC | $738.49 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $702.89 | 2023-2025 | Sotyktu |
| Genzyme Corporation | $661.94 | 2019-2025 | |
| Amgen INC. | $461.91 | 2020-2025 | Otezla, Otezla |
| Ucb, INC. | $448.81 | 2020-2025 | Bimzelx |
| Pfizer INC. | $374.59 | 2019-2024 | |
| Genentech USA, INC. | $358.56 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $355.36 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $315.29 | 2023-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.29 | 2022-2025 | Spevigo |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $164.00 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $141.79 | 2019-2025 | Adbry, Spevigo, Anzupgo |
| Biofrontera INC. | $126.45 | 2022-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Janssen Scientific Affairs, LLC | $112.87 | 2022 | |
| Celgene Corporation | $100.91 | 2019 | |
| Vyne Pharmaceuticals INC. | $77.87 | 2020-2021 | |
| Galderma Laboratories, L.P. | $71.09 | 2022-2025 | Nemluvio |
| Organogenesis INC. | $62.71 | 2019-2024 | Affinity |
| Almirall LLC | $58.22 | 2025 | Seysara |
| Organon LLC | $54.21 | 2025 | Vtama |
| Dusa Pharmaceuticals, INC. | $53.89 | 2019 | |
| Dermavant Sciences, INC. | $52.76 | 2023-2024 | Vtama |
| Smith+Nephew, INC. | $51.04 | 2019-2022 | |
| Epi Health, LLC | $47.86 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $44.18 | 2019 | |
| Merck Sharp & Dohme LLC | $36.86 | 2019-2022 | |
| Strata Skin Sciences, INC. | $29.10 | 2024 | Xtrac |
| Sensus Healthcare, INC. | $28.31 | 2021 | |
| Mallinckrodt Hospital Products INC. | $19.69 | 2025 | Acthar |
| Dermira, INC. | $17.41 | 2019 | |
| Botanix Sb INC | $15.32 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leland Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.